SCHEMBL24896325

SCHEMBL24896325

CC(C)(C)OC(=O)NCCn1c(C(=O)O)cc2ccnc(Cl)c21

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.42
DRD2 P14416 5/20 0.40
ATR Q13535 1/20 0.39
STK17B O94768 1/20 0.39
STK17A Q9UEE5 1/20 0.39
CCR9 P51686 4/20 0.38
STING1 Q86WV6 1/20 0.37
P2RX3 P56373 1/20 0.37
CSNK2A2 P19784 1/20 0.36
CSNK2A1 P68400 1/20 0.36
CKS1B P61024 1/20 0.36
SKP1 P63208 1/20 0.36
SKP2 Q13309 1/20 0.36
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
ADORA2A P29274 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30220584 0.88 DYRK1A (0.41) DYRK1ADRD2ATRSTK17BSTK17A
SCHEMBL30220580 0.88 DYRK1A (0.41) DYRK1ADRD2ATRSTK17BSTK17A
SCHEMBL24896323 0.85 DYRK1A (0.42) DYRK1ADRD2ATRSTK17BSTK17A
SCHEMBL30220542 0.83 DRD2 (0.38) DYRK1ADRD2ATRSTK17BSTK17A
SCHEMBL16590479 0.80 CCR9 (0.56) DRD2STK17BSTK17ACCR9
SCHEMBL29437373 0.78 STK17B (0.49) DRD2STK17BSTK17ACCR9CKS1B
SCHEMBL2723441 0.78 STK17B (0.49) DRD2STK17BSTK17ACCR9CKS1B
SCHEMBL24896363 0.78 SYK (0.42) CCR9P2RX3
SCHEMBL24896565 0.77 CCR9 (0.39) CCR9
SCHEMBL24896371 0.76 GPR35 (0.46) CCR9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4370207-A1 BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS Nido Biosciences, Inc. (US) 2024-05-22 EP disclosed
US-20230039586-A1 BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS NIDO BIOSCIENCES, INC. 2023-02-09 US disclosed
WO-2023287704-A1 BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS NIDO BIOSCIENCES, INC. (US) 2023-01-19 WO disclosed
WO-2023287704-A1 BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS NIDO BIOSCIENCES, INC. (US) 2023-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230039586-A1 BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS AR, FSHR, NR5A1 DYRK1A 3483/4885DRD2 1937/4885ATR 3606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.